CancerCASEMENCT05156931
Exploration of Patient Self-medication Practices During and After Cancer in France
An observational study of Cancer and Self-medication, run by University Hospital, Clermont-Ferrand at 1 site in France.
Trial summary
The purpose of this study is to assess the patient self-medication practices during and after cancer in France, using an online questionnaire Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer, Self-medication
- How many people
- 681 participants
- Where
- 1 siteFrance
- Study dates
- 14 Dec 2021to 30 Apr 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients contacted by cancer patient's association
Who may be able to join
- Past or active cancer
Who cannot join
- Speaking French
- Not living in France
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Exploration of Patient Self-medication Practices During and After Cancer in France: Cross-sectional Observational Study With Online Response
The purpose of this study is to assess the patient self-medication practices during and after cancer in France, using an online questionnaire
Read the detailed description
Patients will be contacted by email from patient's associations. Patients will be informed of the objectives of the study and will be free to answer or not to the online questionnaire.
- Conditions
- Cancer, Self-medication
- Keywords
- cancer, self-medication, quality of life
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Self-medication
declaration of a practice of self-medication
Measured: day 1
Secondary outcomes (5)
Class of products used in self-medication
non-prescription medicine, herbal medicine, aromatherapy, homeopathy, and food supplements
Measured: day 1
Indication for self-medication
For treatment of side-effects, improvements in anti-cancer effects
Measured: day 1
Origin of self-medication products
pharmacy, market, internet, other
Measured: day 1
Perception of adverse effects and drug-drug interaction related to self medication
yes / no
Measured: day 1
QLQ-C30 questionnaire
Global health status Functional scales Physical functioning Role functioning Emotional functioning Cognitive functioning Social functioning Fatigue Nausea and vomiting Pain Dyspnoea Insomnia Appetite loss Constipation Diarrhoea Financial difficulties
Measured: day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Dec 2021
- Study start14 Dec 2021
- Primary completion30 Apr 2022
- Study completion30 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University Hospital, Clermont-FerrandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 681 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05156931
- Sponsor's protocol ID
- RNI 2021 BALAYSSAC
- Acronym
- CASEME
- Status last verified
- Aug 2026
- First submitted
- 1 Dec 2021
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Maraud J, Bedhomme S, Pereira B, Trevis S, Jary M, Balayssac D. Self-Medication during and after Cancer: A French Nation-Wide Cross-Sectional Study. Cancers (Basel). 2023 Jun 15;15(12):3190. doi: 10.3390/cancers15123190.
PubMed 37370800
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploration of Patient Self-medication Practices During and After Cancer in France: Cross-sectional Observational Study With Online Response
- ClinicalTrials.gov ID
- NCT05156931
- Acronym / sponsor ID
- CASEME / RNI 2021 BALAYSSAC
- Conditions
- Cancer, Self-medication
- Keywords
- cancer, self-medication, quality of life
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 681 participants (actual)
- Lead sponsor
- University Hospital, Clermont-FerrandUniversity, hospital or other
- Study start
- 14 Dec 2021 (actual)
- Primary completion
- 30 Apr 2022 (actual)
- Study completion
- 30 Apr 2022 (actual)
- First posted
- 14 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the patient self-medication practices during and after cancer in France, using an online questionnaire
Detailed description
Patients will be contacted by email from patient's associations. Patients will be informed of the objectives of the study and will be free to answer or not to the online questionnaire.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients contacted by cancer patient's association
Key inclusion criteria (1 listed)
- Past or active cancer
Key exclusion criteria (2 listed)
- Speaking French
- Not living in France
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Self-medication
Time frame: day 1
declaration of a practice of self-medication
5 secondary outcomes
Class of products used in self-medication
Time frame: day 1
Indication for self-medication
Time frame: day 1
Origin of self-medication products
Time frame: day 1
Perception of adverse effects and drug-drug interaction related to self medication
Time frame: day 1
QLQ-C30 questionnaire
Time frame: day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
- Results publication: PubMed 37370800Maraud J, Bedhomme S, Pereira B, Trevis S, Jary M, Balayssac D. Self-Medication during and after Cancer: A French Nation-Wide Cross-Sectional Study. Cancers (Basel). 2023 Jun 15;15(12):3190. doi: 10.3390/cancers15123190.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Self-medication, run by University Hospital, Clermont-Ferrand at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Self-medication (time frame: day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05156931, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.